Stockscreener 앱 받기
1.41
0.71%
0.01
시간 외 거래:
1.38
-0.03
-2.13%
전일 마감가:
$1.40
열려 있는:
$1.44
하루 거래량:
425.75K
Relative Volume:
1.90
시가총액:
$126.48M
수익:
-
순이익/손실:
$-30.15M
주가수익비율:
-1.5495
EPS:
-0.91
순현금흐름:
$-31.63M
1주 성능:
+16.53%
1개월 성능:
+68.86%
6개월 성능:
+80.75%
1년 성능:
-28.06%
1일 변동 폭
$1.3702
$1.515
1주일 범위
$1.085
$1.55
52주 변동 폭
$0.49
$2.5899
Context Therapeutics Inc Stock (CNTX) Company Profile
명칭
Context Therapeutics Inc
전화
267-225-7416
주소
2001 MARKET STREET, PHILADELPHIA
CNTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.41 | 125.59M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | JMP Securities | Mkt Outperform |
| 2024-11-25 | 개시 | D. Boral Capital | Buy |
| 2024-05-16 | 개시 | Piper Sandler | Overweight |
Context Therapeutics Inc 주식(CNTX)의 최신 뉴스
How to use Fibonacci retracement on Context Therapeutics Inc.2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Is Context Therapeutics Inc. stock positioned well for digital economyMarket Rally & Verified Short-Term Plans - newser.com
Momentum divergence signals in Context Therapeutics Inc. chart2025 Big Picture & AI Powered Trade Plan Recommendations - newser.com
Can a trend reversal in Context Therapeutics Inc. lead to recoveryEarnings Recap Report & Fast Moving Stock Watchlists - newser.com
Context Therapeutics to Present New Data on Two Bispecific T Cell Engagers at SITC 2025 - MyChesCo
Context Therapeutics to Showcase CT-95 Data at AACR 2025 - MSN
What drives Context Therapeutics Inc stock priceCandlestick Trading Patterns & Unlock Patterns Humans Can’t See - earlytimes.in
Is Context Therapeutics Inc. stock ready for a breakoutNew Guidance & Low Risk Entry Point Tips - newser.com
Will Context Therapeutics Inc. continue its uptrendLayoff News & AI Based Buy and Sell Signals - newser.com
Historical volatility pattern of Context Therapeutics Inc. visualizedQuarterly Earnings Summary & Community Supported Trade Ideas - newser.com
Real time social sentiment graph for Context Therapeutics Inc.Portfolio Update Summary & Free Weekly Watchlist of Top Performers - newser.com
Live market analysis of Context Therapeutics Inc.July 2025 Market Mood & Stepwise Swing Trade Plans - newser.com
Context Therapeutics Inc. stock momentum explained2025 Dividend Review & Risk Controlled Daily Trade Plans - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Context Therapeutics (NASDAQ:CNTX) - MarketBeat
How Context Therapeutics Inc. stock trades before earningsQuarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Is a relief rally coming for Context Therapeutics Inc. holdersIndex Update & AI Driven Stock Reports - newser.com
Is Context Therapeutics Inc. showing signs of accumulationEarnings Summary Report & Stepwise Trade Signal Implementation - newser.com
Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the most - Yahoo Finance
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.20 Consensus PT from Analysts - Defense World
Context Therapeutics Grants Stock Options to New Hire - MSN
Will Context Therapeutics Inc. see short term momentumJuly 2025 Short Interest & Fast Moving Stock Watchlists - newser.com
Context Therapeutics Announces Poster Presentations at the - GlobeNewswire
Context Therapeutics Inc. to Present Trial Progress and Preclinical Data at SITC 2025 Annual Meeting - Quiver Quantitative
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of ... - Caledonian Record
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Stock Titan
Is it too late to sell Context Therapeutics Inc.2025 Winners & Losers & High Win Rate Trade Tips - newser.com
Context Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - MarketScreener
Developing predictive dashboards with Context Therapeutics Inc. dataJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Context Therapeutics announces inducement grant under Nasdaq listing rule - MarketScreener
GlobeNewswire by Notified - The Manila Times
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
30,000-Share Option: Context Therapeutics Grants New Hire Award at $0.97 Exercise Price, 10-year Term - Stock Titan
Context Therapeutics Gains 11%, Insider Trades Reap Benefit - simplywall.st
Is Context Therapeutics Inc. stock in correction or buying zoneWeekly Trade Recap & Free Community Consensus Stock Picks - newser.com
Context Therapeutics Inc (CNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
자본화:
|
볼륨(24시간):